Viscofan World You are in: The Viscofan Group EN | ES
Global

The Viscofan Group

EN | ES
Europe

Belgium

EN

Czech Republic

CS | EN

Germany

DE

Serbia

EN | SR

Spain

ES
Americas

Brazil

PT

Canada

EN | FR

Mexico

ES

United States

EN

Uruguay

ES
Asia & Oceania
Viscofan BioEngineering
Viscofan releases 9M23 results
30/October/2023

​Main conclusions of the January-September 2023 results:

Revenue increased by 6.1% to €926.2 million, and by 7.9% in like-for-like terms.

• EBITDA increased by 1.1% to €192.6 million, and by 8.9% in like-for-like terms.

• Net profit was 4.1% lower at €100.8 million.

• Net bank debt in September 2023 at €108.6 million was 24.7% lower than the €144.2 million in June 2023 driven by the improvement in cash flow generation in the quarter thanks to the lower investment needs and initiatives to reduce working capital.

• José Domingo de Ampuero y Osma, Chairman of the Viscofan Group: “Inventory adjustment initiatives by casing customers are causing worse than expected market performance, particularly in the Asia Pacific area.

This temporary market situation coincides with a high-cost environment and an unfavourable currency environment that is putting pressure on our margins.

On the other hand, from an operational point of view, the Viscofan Group continues to show great strength, where the results obtained in the machines with the new technology and the cost control implemented allow us to achieve solid growth in revenue and EBITDA in like-for-like terms, reinforcing our vision about the expected margin improvement for 2024 and our Beyond25 strategic plan”.

You can find all results information on the Investor Relations site

® Viscofan Group